Premium
A comparative study of once‐daily versus twice‐daily filgrastim administration for the mobilization and collection of CD34 + peripheral blood progenitor cells in normal donors
Author(s) -
Anderlini Paolo,
Donato Michele,
Lauppe Mary J.,
Huh Yang O.,
Martin Thomas G.,
Chan KaWah,
Champlin Richard E.,
Körbling Martin
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02083.x
Subject(s) - filgrastim , leukapheresis , apheresis , medicine , cd34 , progenitor cell , peripheral blood , liter , urology , granulocyte colony stimulating factor , surgery , stem cell , chemotherapy , platelet , biology , genetics
Eighty‐one first‐time normal donors underwent leukapheresis for peripheral blood progenitor cell (PBPC) collection after mobilization with filgrastim administered either twice‐daily (6 µg/kg every 12 h; n = 40) or once‐daily (12 µg/kg; n = 41) subcutaneously for 3 d. The groups were similar for age, donor blood volume and target CD34 + cell dose to be collected (≥ 4 × 10 6 CD34 + cells/kg recipient). There was no statistically significant difference in the apheresis yield of CD34 + PBPCs (× 10 6 ) per kg recipient weight (5·6 ± 3·3 vs. 5·6 ± 4·3; P = 0·94) and per litre of blood processed (30 ± 17·2 vs. 30·4 ± 19·5; P = 0·92).